Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05928689 · ClinicalTrials.gov registry record · Early Phase 1
Behavioral and Pharmacological Reconsolidation Interference in Misophonia
A Early Phase 1 study, sponsored by Icahn School of Medicine at Mount Sinai.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 141
- Enrollment target
NCT05928689: Completed Early Phase 1 study, sponsored by Icahn School of Medicine at Mount Sinai.
NCT05928689 is a Early Phase 1 study that has completed, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 141 participants, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (166% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05928689, a Early Phase 1 study, has completed, sponsored by Icahn School of Medicine at Mount Sinai.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 141 participants
- Enrollment target
Study Summary
One of the core processes presumably underlying misophonia - a condition characterized by decreased tolerance for specific sounds - is associative learning. Using behavioral, computational, and neural analyses of emotional learning and memory processes to understand the unknown behavioral and neural mechanisms underlying misophonia's associative learning and memory, the study team will evaluate whether interference with the reconsolidation of a reactivated misophonia memory with propranolol can alleviate aversive reaction to misophonia-related cues.
Primary Outcome
Using galvanic skin response based on deflections of a wave, a difference between the average response to the misophonia-related video before and after the pharmacological or behavioral manipulation will be measured. The difference in scores across conditions will be compared. A greater deflection indicates greater sympathetic nervous system arousal.
Interventions
- DRUG Placebo
- BEHAVIORAL Reminder
- DRUG Propranolol Hydrochloride tablet
- BEHAVIORAL Counterconditioning
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 141 participants |
| Start Date | 2023-06-02 |
| Est. Completion | 2024-09-30 |
| Phase | Early Phase 1 |
What the finished NCT05928689 record still lists
NCT05928689 is an interventional study that assigns participants to a tested intervention. The registered 141 participants enrollment target is mid-sized for trials with a published cap, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (166% higher).
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT05928689 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05928689 about?
NCT05928689 is a clinical study titled "Behavioral and Pharmacological Reconsolidation Interference in Misophonia". One of the core processes presumably underlying misophonia - a condition characterized by decreased tolerance for specific sounds - is associative learning. Using behavioral, computational, and neural analyses of emotional learning and memory processes to understand the unknown behavioral and neural...
What is the current status of trial NCT05928689?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 141 participants. The study started on 2023-06-02. Estimated completion is 2024-09-30.
What interventions are being tested in trial NCT05928689?
The interventions under investigation include: Placebo (DRUG), Reminder (BEHAVIORAL), Propranolol Hydrochloride tablet (DRUG), Counterconditioning (BEHAVIORAL).
Who is sponsoring clinical trial NCT05928689?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05928689's enrollment target sits among peer trials
141 116th of 2000 higher than 1,884 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03042962 · 141 participants
Brain Networks in Dystonia
- NCT04378439 · 141 participants · NA
Appalachian Partnership to Reduce Disparities (Aim 2)
- NCT04775485 · 141 participants · Phase 2
A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors
- NCT05040360 · 141 participants · Phase 2
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI